In Silico Study of Coumarins: Wedelolactone as a Potential Inhibitor of the Spike Protein of the SARS-CoV-2 Variants
Authors:
Open Access
- 6 February 2023
- journal article
- research article
- Published by Wiley in Journal of Tropical Medicine
- Vol. 2023, 1-19
Abstract
Despite the rigorous global efforts to control SARS-CoV-2 transmission, it continues to pose a serious threat to humans with the frequent emergence of new variants. Thus, robust therapeutics to combat the virus are a desperate need. The SARS-CoV-2 spike (S) protein is an important target protein as it mediates the entry of the virus inside the host cells, which is initiated by the binding of the receptor-binding domain (RBD) to its cognate receptor, angiotensin-converting enzyme 2 (ACE-2). Herein, the inhibition potential of several naturally occurring coumarins was investigated against the spike proteins of SARS-CoV-2 variants using computational approaches. Molecular docking studies revealed 26 coumarins with better binding energies than the reference ligands, molnupiravir and ceftazidime, against the S-RBD of the omicron variant. The top 10 best-docked coumarins were further analyzed to understand their binding interactions against the spike proteins of other variants (wild-type, Alpha, Beta, Gamma, and Delta), and these studies also demonstrated decent binding energies. Physicochemical, QSAR, and pharmacokinetics analyses of the coumarins revealed wedelolactone as the best inhibitor of the spike protein with ideal Lipinski’s drug-likeness and optimal ADMET properties. Furthermore, coarse-grained molecular dynamics (MD) simulation studies of spike protein-wedelolactone complexes validated the stable binding of wedelolactone in the respective binding pockets. As an outcome, wedelolactone could be utilized to develop a potent drug candidate against COVID-19 by blocking the viral entry into the host cell.Keywords
Funding Information
- University Grants Commission- Nepal (CoV-76/77-02)
This publication has 49 references indexed in Scilit:
- Anti‐hepatitis C virus compounds obtained from Glycyrrhiza uralensis and other Glycyrrhiza speciesMicrobiology and Immunology, 2014
- Molecular docking studies for the identification of novel melatoninergic inhibitors for acetylserotonin-O-methyltransferase using different docking routinesTheoretical Biology and Medical Modelling, 2013
- P-glycoprotein Inhibition for Optimal Drug DeliveryDrug Target Insights, 2013
- Optimized Hydrophobic Interactions and Hydrogen Bonding at the Target-Ligand Interface Leads the Pathways of Drug-DesigningPLOS ONE, 2010
- AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreadingJournal of Computational Chemistry, 2009
- Assessing Scoring Functions for Protein−Ligand InteractionsJournal of Medicinal Chemistry, 2004
- Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings 1PII of original article: S0169-409X(96)00423-1. The article was originally published in Advanced Drug Delivery Reviews 23 (1997) 3–25. 1Advanced Drug Delivery Reviews, 2001
- A Prenyloxycoumarin from Psiadia dentata.Chemical and Pharmaceutical Bulletin, 2001
- Coumarins and anti-HBV constituents from Zanthoxylum schinifoliumPhytochemistry, 1997
- The inophyllums, novel inhibitors of HIV-1 reverse transcriptase isolated from the Malaysian tree, Calophyllum inophyllum LinnJournal of Medicinal Chemistry, 1993